Metabolism Disorder TRIZ Cases
- Anti-PCSK9 Antibodies for LDL-C Reduction
Fully human monoclonal antibodies block PCSK9 binding to LDL receptors, restoring cellular uptake and reducing circulating LDL-C concentrations.
- Virus-like Particle Immunogen for Triglyceride Reduction
A virus-like particle immunogen elicits antibody responses against angiopoietin-like polypeptides to inhibit lipoprotein lipase activity.
- ACAT1 Selective Inhibitors for Obesity Treatment
Segmenting ACAT isoforms preserves cholesterol homeostasis while treating obesity.
- S-nitrosylating Agents Restore VLCAD Enzymatic Activity
S-nitrosylating agents restore VLCAD enzymatic activity, reducing liver triglycerides and treating very long-chain acyl-CoA dehydrogenase deficiency.
- rAAV Vector Gene Therapy for Fabry Disease Enzyme Delivery
Recombinant adeno-associated viral vectors deliver the GLA gene to target tissues, enabling sustained alpha-GAL enzyme production.
- Intrathecal I2S Enzyme Delivery for Hunter Syndrome CNS Treatment
Intrathecal recombinant iduronate-2-sulfatase administration delivers therapeutic enzyme directly to the central nervous system.
- Glucagon Analog Stability via Residue Mutations
Mutating residues 24, 25, and 27 in glucagon analogs prevents fibrillation and deamidation at physiological pH.
- Trigonal Peptidic Agonists for Metabolic Disorder Treatment
Chimeric trigonal agonists merge exendin-4 with glucagon sequences to enhance solubility, stability, and multi-receptor activation efficacy.
- Valine-Free Nutrition Formula for Hematopoietic Stem Cell Depletion
Withholding valine in parenteral or enteral formulas eliminates hematopoietic stem cells without radiation-induced tissue damage.
- Molecular Probe for Noninvasive Pancreatic Islet Imaging
A molecular probe targets pancreatic islets via GLP-1R binding for PET or SPECT imaging.
- Monoclonal Antibodies Targeting ANGPTL3 for Lipid Metabolism
Monoclonal antibodies neutralize ANGPTL3 activity to lower serum lipid concentrations, addressing underlying metabolic dysfunction in hypertriglyceridemia.
- Aromatic-Cationic Peptides for Metabolic Syndrome Treatment
Aromatic-cationic peptides treat metabolic syndrome by improving lipid metabolism and blood sugar levels.
- Hydroquinone Ansamycins for Soluble Hsp90 Inhibition
Hydroquinone ansamycins resolve low solubility and hepatotoxicity of geldanamycin by adding hydroxyl groups to improve delivery.
- Glucagon Analogue Peptides Dual Receptor Agonism
Novel glucagon analogue peptides act as dual agonists for glucagon and GLP-1 receptors to modulate metabolic functions.
- Lactobacillus plantarum LP10 Probiotic for Body Fat Reduction
Lactobacillus plantarum LP10 reduces body fat without adverse effects by mediating lipid metabolism at dosages exceeding 3×10^10 CFU daily.
- Amphiphilic Polymer Microparticles for Sustained Hydrophilic Drug Release
Agglomerated amphiphilic polymer microparticles prevent initial burst and sustain release of hydrophilic drugs via controlled degradation.
- PCSK9 Inhibitors for PCSK9 Gain-of-Function Mutation Treatment
Anti-PCSK9 antibodies target pathological protein activity to lower serum LDL cholesterol levels in patients with autosomal dominant hypercholesterolemia.
- Cardiosphere-Derived Exosomes for Systemic GVHD Treatment
Cardiosphere-derived exosomes reduce inflammation and fibrosis, addressing limited efficacy of corticosteroids in chronic GVHD.
- Antibody Fragments Modulate Insulin Receptor Binding to Prevent Hypoglycemia
Negative modulator antibody fragments block insulin-receptor binding to prevent recurrent hypoglycemia and improve glycemic control.
- SHP2 Inhibitors for Insulin Resistance via Liver-Targeted Delivery
Liver-targeting nanoparticles deliver SHP2 inhibitors to alleviate insulin resistance while minimizing off-target toxicity.
- Insulin Secreting Polypeptides Resolving Cardiorenal Trade-offs
Amino acid modifications in GLP-1 polypeptides resolve the trade-off between glucose lowering and cardiorenal protection.
- 64Zn-Enriched Zinc for NASH Treatment
64Zn-enriched zinc reduces liver inflammation and fat accumulation while minimizing toxic side effects associated with traditional therapies.
- CB1 Antibody Segmentation for Peripheral Metabolic Targeting
Segmenting CB1 receptors via large molecule antibodies blocks peripheral signaling without CNS penetration, reducing adverse effects.